Clinical Cancer Research Grants Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 2054, April 1, 2007. doi: 10.1158/1078-0432.CCR-06-2299
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, C.-Y.
Right arrow Articles by Lin, J.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, C.-Y.
Right arrow Articles by Lin, J.-T.

Imaging, Diagnosis, Prognosis

Plasma Matrix Metalloproteinase-9 Level Is Better than Serum Matrix Metalloproteinase-9 Level to Predict Gastric Cancer Evolution

Chun-Ying Wu1,4,6, Ming-Shiang Wu2, En-Pei Chiang7, Yi-Ju Chen5, Chien-Jen Chen3, Nai-Hui Chi2, Ying-Ting Shih7, Gran-Hum Chen2 and Jaw-Town Lin2

Authors' Affiliations: 1 Graduate Institute of Clinical Medicine, College of Medicine; 2 Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital; 3 Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan; 4 Division of Gastroenterology and 5 Department of Dermatology, Taichung Veterans General Hospital; 6 College of Public Health, China Medical University; and 7 Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan

Requests for reprints: Jaw-Town Lin, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Section 1, Chung-Shan S. Road, Taipei, 10017, Taiwan. Phone: 886-2-23562246; Fax: 886-2-23947899; E-mail: jawtown{at}ha.mc.ntu.edu.tw.

Purpose: Matrix metalloproteinase-9 (MMP-9) in blood is a promising new tumor marker. The aims of the present study are to compare the usefulness of plasma and serum MMP-9 levels for predicting gastric cancer development, invasion, and survival.

Experimental Design: In this nested case-control study, 114 gastric cancer patients and 87 healthy controls were enrolled. MMP-9 levels and activities were quantitatively measured by ELISA assay and zymography. The results were compared with the occurrence, clinicopathologic features, and outcomes of gastric cancer patients. The follow-up time for all patients was at least 5 years.

Results: Serum MMP-9 levels were significantly higher than plasma MMP-9 levels. Both plasma and serum MMP-9 levels correlated significantly with active MMP-9 identified by zymography (P = 0.002 and P = 0.048, respectively). Plasma MMP-9 level was significantly elevated in gastric cancer patients when compared with control subjects (P < 0.001). Serum MMP-9 levels did not differ between the groups. Receiver-operator characteristics analysis showed the values of sensitivity (82.5%) and specificity (65.5%) at the maximum accuracy for plasma MMP-9 at ≥60 ng/mL (P < 0.001). Elevated plasma MMP-9 correlated significantly with lymph node metastasis [odds ratio (OR), 3.43; P = 0.019], lymphatic invasion (OR, 7.58; P = 0.009), and venous invasion (OR, 4.14; P = 0.033). Patients with elevated plasma MMP-9 levels had poorer survival rates than those with normal plasma MMP-9 levels (P = 0.038). Serum MMP-9 level did not correlate well with gastric cancer–invasive phenotypes or survival.

Conclusion: Our results suggest plasma MMP-9 level is a better marker than serum MMP-9 level for predicting gastric cancer development and progression.




This article has been cited by other articles:


Home page
Mol. Cell. ProteomicsHome page
C. Lausted, Z. Hu, and L. Hood
Quantitative Serum Proteomics from Surface Plasmon Resonance Imaging
Mol. Cell. Proteomics, December 1, 2008; 7(12): 2464 - 2474.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
K. Jung
Matrix metalloproteinases do not properly work as peripheral blood biomarkers without taking into account the preanalytical impact of blood sampling
Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 944 - 944.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Jung
Matrix Metalloproteinase-8 and Tissue Inhibitor of Metalloproteinase-1 in Serum Do Not Reflect the Analytes Circulating in Blood
Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): e15 - e16.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y.-H. Yang, H. Deng, W.-M. Li, Q.-Y. Zhang, X.-T. Hu, B. Xiao, H.-H. Zhu, P.-L. Geng, and Y.-Y. Lu
Identification of Matrix Metalloproteinase 11 as a Predictive Tumor Marker in Serum Based on Gene Expression Profiling
Clin. Cancer Res., January 1, 2008; 14(1): 74 - 81.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
S.-F. Yang, P.-H. Wang, L.-Y. Lin, J.-L. Ko, G.-D. Chen, J.-S. Yang, H.-S. Lee, and Y.-S. Hsieh
A Significant Elevation of Plasma Level of Matrix Metalloproteinase 9 in Patients With High-Grade Intraepithelial Neoplasia and Early Squamous Cell Carcinoma of the Uterine Cervix
Reproductive Sciences, October 1, 2007; 14(7): 710 - 718.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.